PAX5 and leukemia: In contrast, the latency to leukemia in Pax5+/−mice treated with poly(I:C) was significantly longer than in the Pax5+/−control group receiving vehicle, where it was delayed until 12–21 months of age (p = 0.0019) (Fig. 6e).